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Background: Earlier, we reported a highly statistically significant association between T-helper 1 (Th1) and Th2
cytokine genotypes and hepatocellular carcinoma (HCC) risk among natives of southern Guangxi, China, a
hyperendemic region for HCC. Epidermal growth factor (EGF) plays a critical role in malignant transformation of
hepatocytes and tumor progression. A polymorphism in the EGF gene (61A > G) results in elevation of EGF in liver
tissues and blood. Epidemiological data are sparse on the possible association between EGF genetic polymorphism
and HCC risk.
Methods: The EGF 61A > G polymorphism, multiple Th1 and Th2 genotypes, and environmental risk factors for HCC
were determined on 117 HCC cases and 225 healthy control subjects among non-Asians of Los Angeles County,
California, a low-risk population for HCC, and 250 HCC cases and 245 controls of southern Guangxi, China.
Results: Following adjustment for all known or suspected HCC risk factors, non-Asians in Los Angeles who
possessed at least one copy of the high activity 61*G allele of the EGF gene showed a statistically non-significant,
78% increased risk of HCC compared with those possessing the EGF A/A genotype. This EGF-HCC risk association
significantly strengthened among heavy users of alcohol [odds ratio (OR) = 3.44, 95% confidence interval
(CI) = 0.93–12.76, P = 0.065)], and among individuals carrying the high-risk Th1/Th2 genotypes for HCC (OR = 3.34,
95% CI = 1.24-9.03, P = 0.017). No association between EGF genotype and HCC risk was observed among Chinese in
southern Guangxi, China.
Conclusion: Genetic polymorphism in the EGF gene resulting in elevated level of EGF, may contribute to HCC risk
among low-risk non-Asians in Los Angeles.
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Hepatocellular carcinoma (HCC) is the sixth most
common cancer worldwide and the third leading cause
of cancer deaths [1]. The incidence of HCC and the dis-
tribution of HCC risk factors vary widely in different
geographic regions worldwide. China and Africa are
areas of high HCC incidence where the primary cause of* Correspondence: yuanj@upmc.edu
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reproduction in any medium, provided the orHCC is chronic infections with the hepatitis B virus
(HBV), and dietary aflatoxin exposure being an import-
ant cofactor [2,3]. In low HCC incidence areas including
Europe and North America, diverse environmental
factors, including chronic HBV and hepatitis C virus
(HCV) infections, heavy alcohol use, diabetes, obesity,
and tobacco use have been shown to contribute to the
local burden of HCC [3-6]. However, only a minority of
people with established risk factors eventually develop
HCC, suggesting that other environmental and/or gen-
etic factors may play a role in HCC development.
Among currently well-established risk factors, inflam-
mation represents a common molecular pathway ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in response to infectious agents or tissue injury where
initially pro-inflammatory cytokines (Th1) are released
to fight off infection or induce tissue remodeling. Once
the infection is cleared or tissue damage is healed, the
anti-inflammatory (Th2) cytokines are released to re-
solve inflammation and establish homeostasis. In chronic
inflammation, however, the inflammatory process per-
sists over prolonged periods of time and the continual
cell death/regeneration accompanying the process is
recognized to enhance risk of cancer, including HCC
(reviewed in [8]). In HCC, hepatic injury can be induced
by viruses (HBV or HCV), alcohol, or aflatoxin exposure
[7]. The resultant necro-inflammatory process, where
necrosis is followed by hepatocyte proliferation, leads to
a continuous cycle of cell destruction/regeneration cha-
racterized by abnormal nodules surrounded by collagen
deposit and tissue scarring. The nodules can progress
from a hyperplastic to a dysplastic phase and ultimately
to HCC [7].
Epidermal growth factor (EGF) is a mitogen for
hepatocytes [9], and plays a critical role in liver tissue re-
generation [10]. Mounting evidence supports a role for
EGF in malignant transformation, tumor growth and
progression [11]. Over-expression of a secreted human
EGF fusion protein enhances the transformation of
fibroblasts to fibrosarcomas and induces the develop-
ment of HCC in transgenic mice [12,13]. Gene expres-
sion profiles comparing normal liver tissue with liver
tumors in these mice suggest a role for an autocrine
mechanism during EGF-induced hepatocarcinogenesis
[12]. A functional polymorphism in EGF at position 61
(A > G) (SNP rs4444903) was recently identified with the
G/G genotype associating with higher gene expression
compared to the A/A genotype [14]. Similarly, increased
EGF expression was reported in serum and liver tissue
from HCC patients with the G/G genotype [14], and cir-
rhotic patients with the G/G genotype were more likely
to progress and develop HCC than cirrhotic patients
with the A/A genotype [15]. Interestingly, G/G genotype
was associated with elevated risk of other malignancies,
including glioma [16], malignant melanoma [14], gastric
cancer [17], esophageal adenocarcinoma [18], and lung
cancer [19].
Utilizing two existing case–control study databases, we
examined the association between EGF 61A > G poly-
morphism and HCC risk in two populations at polar
ends of the HCC risk spectrum. The Chinese in south-
ern Guangxi, China, exhibit the highest recorded inci-
dence rate of HCC in the world (120 per 100,000
person-years in men) [20] while the non-Asians in Los
Angeles, California, USA possess one of the lowest inci-
dence rate of HCC in the world (4 per 100,000 person-
years among non-Hispanic white men) [21]. In thepresent study, we also examined the EGF genotype –
HCC risk association across different risk strata defined
by genetic profiles (Th1/Th2 cytokine genotypes) or
environmental exposures (use of alcohol or tobacco,
hepatitis serology status) within each of the two study
populations.Methods
The present study included participants of two case–
control studies of HCC, one conducted among low-risk
non-Asians in Los Angeles, California, and the other
conducted in high-risk Chinese in the southern part of
the Guangxi Autonomous Region, China. The designs of
the two studies have been described previously [6,22].
Permission to conduct this study had been obtained
from the Institutional Review Boards at the University of
Southern California and the Guangxi Cancer Institute.
Separate informed consent forms for interview and
biospecimen collection were obtained from each study
participant.HCC patients
In Los Angeles, we studied incident HCC in black, and
Hispanic and non-Hispanic white residents of Los
Angeles County, who were between 18 and 74 years of
age at diagnosis from January 1984 through December
2001. Cases were identified through the Los Angeles
County Cancer Surveillance Program, a population-
based cancer registry that records all incident cancers
diagnosed in residents of Los Angeles County. Due to
the rapidly fatal nature of HCC (the median time interval
between diagnosis and death is approximately 3 months),
84% of eligible patients died prior to our attempted con-
tact. Among the 478 patients we contacted, 34 (7%) were
too ill to be interviewed, and 325 (73%) of the remaining
444 were interviewed. An experienced hepatopathologist
reviewed the histology slides of all interviewed HCC
patients; 25 cases judged to be non-HCC were excluded.
Virtually all histologically confirmed HCC patients had an
underlying cirrhosis.
In Guangxi, China, we identified newly diagnosed
HCC from four major hospitals in the city of Nanning.
Participating hospitals were comparable in their quality
of patient care and diagnosis. Only patients diagnosed
during September 1995 through September 1998, be-
tween the ages of 20 and 64 years, and residing in Nan-
ning City or its neighboring townships were asked to
participate in the study. We began the study in October
1995 and closed enrollment in October 1998 when 250
patients had been recruited into the study. Among the
250 HCC patients, 40 (16%) were diagnosed histologically,
162 (65%) were diagnosed by positive serum α-fetoprotein
level above 500 ng/ml persistent for more than one month
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(19%) were diagnosed with imaging/clinical evidence only.Control subjects
In Los Angeles, we sought to recruit up to two control
subjects per case from the neighborhoods where HCC
patients resided at the time of diagnosis, who were
matched to the index case by sex, age (within 5 years),
and race (Hispanic white, non-Hispanic white, black). A
total of 474 neighborhood control subjects were re-
cruited into the study; most were the first (74%) or sec-
ond (12%) eligible neighbors.
In Guangxi, China, we identified one consenting con-
trol subject per case among all patients admitted to the
same hospital within one month of the index case’s
hospital admission, who had no history of cancer or
clinical liver cirrhosis. The matching criteria were age
(within 3 years), gender, ethnicity (Han, Zhuang, Yao,
other), and district (if resident of Nanning City) or town-
ship (if resident of neighboring townships) of residence.Data collection
All consenting cases and control subjects in Los Angeles,
California and Guangxi, China were interviewed in person
by trained interviewers using structured questionnaires.
Both the Los Angeles and Guangxi questionnaires so-
licited demographic information, lifetime use of tobacco
and alcohol, medical history, and other lifestyle factors.
An alcohol drinker was defined as someone who had
drunk alcoholic beverages at least once a week for six
months or longer. One drink was defined as 360 g of beer
(12.6 g of ethanol), 103 g of wine (12.3 g of ethanol), or
30 g of spirit (12.9 g of ethanol). A smoker was defined as
someone who had ever smoked on a daily basis. Smokers
were asked at what age (years) they began smoking on a
daily basis, the average number of cigarettes smoked per
day, and total number of years of smoking. Former
smokers were asked about the number of years since
smoking cessation.
Serum and buffy coat samples were collected from all
subjects of the Guangxi study (250 cases and 250
controls). For the Los Angeles study, we collected from
study subjects serum samples beginning in January 1992
and buffy coat samples beginning in October 1995. The
buffy coat samples were available on 120 (73%) of 164
eligible HCC cases (i.e., those interviewed after October
1995). For the 277 control subjects from whom DNA
donation was sought, 230 (83%) consented and donated
blood samples. We examined and found no differences
in the distributions by age, gender, level of education,
cigarette smoking, alcohol consumption, history of dia-
betes, and serologic markers for HBV and HCV infections
between subjects with DNA (i.e., those included in thepresent study) and those without DNA, both for the HCC
cases and for the control subjects.Laboratory tests
Blood samples from cases and controls were processed
and stored (−20°C) in an identical manner. The assays
used for testing serologic markers of HBV and HCV
infections have been described previously [6,22]. Briefly,
we tested all study samples for the presence of hepatitis B
surface antigen (HBsAg) in serum using commercialized
kits (AUSRIA, Abbott Laboratories, North Chicago, IL),
and negative samples (for the Los Angeles study only)
were further tested for the presence of antibodies to the
hepatitis B core antigen (anti-HBc) using standard testing
kits (Corab, Abbott Laboratories, North Chicago, IL). All
samples were tested for the presence of antibodies to the
hepatitis C virus (anti-HCV) in serum using the ELISA
version 2.0 kit manufactured by Ortho Diagnostic
Systems, with confirmation of positive samples using
RIBA version 2.0 (Chiron, Emeryville, CA). Serum samples
were tested blindly, identified only by codes without
regard to case/control status.
DNA was purified from buffy coats of peripheral blood
using a QIAamp 96 Blood Kit (Qiagen, Valencia, CA).
Genotyping assay was developed for the EGF 61A > G
polymorphisms using the fluorogenic 5'-nuclease assay
(TaqMan Assay) according to the allele-specific primers
described previously [15]. The genotyping assays were
carried out on TaqMan using a PCR Core Reagent kit
(Applied Biosystems, Foster City, CA) according to
manufacturer’s instructions. The following oligonucleo-
tide primer sequences (Integrated DNA Technology,
Coralville, IA) were used for PCR amplification of cDNA,
EGF forward: CTTGTCATGCTGCTCCTCCT, reverse:
GAGGGCATATGAAAGCTTCG and β2-microglobulin
forward: TTTCATCCATCCGACATTGA, reverse: ATCT
TCAAACCTCCATGATG. PCR amplification using ~10 ng
of genomic DNA was performed in a thermal cycler
(MWG Biotech, High Point, NC) with an initial step of
95°C for 10 minutes, followed by 50 cycles of 95°C for
25 seconds and 1 minute at the annealing temperature
(Ta, Appendix A). The fluorescence profile of each well
was measured in an ABI 7900HT Sequence Detection
System and the results analyzed with Sequence Detection
Software (Applied Biosystems). Experimental samples
were compared to 12 standard controls to identify the 3
genotypes at each locus. Any samples that were outside
the parameters defined by the controls were identified as
non-informative and were retested. We previously des-
cribed in detail the assays for genetic polymorphisms in
Th1 cytokine genes including interferon γ, interleukin 2
(IL2), IL12 and IL18 and in Th2 cytokine genes including
IL4 and IL10 [22,23].
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ten controls (5 of non-Asians in Los Angeles and 5 of
Chinese in Guangxi, China) were non-informative in the
EGF genetic polymorphism. These subjects were
excluded. Thus, the present analysis included 367 HCC
cases (117 non-Asians and 250 Chinese) and 470 control
subjects (225 non-Asians and 245 Chinese).
Statistical analysis
Chi-square test was used to examine differences in the
distributions of selected demographic variables and the
EGF 61A > G genotype frequencies between cases and
controls by race/ethnicity. The student t test was used to
examine the difference in age between cases and
controls. Unconditional logistic regression models [24]
were used to examine the associations between the EGF
61A > G polymorphism and risk of HCC. The strength
of a gene-HCC risk association was measured by its
odds ratio (OR), and its corresponding 95% confidence
interval (CI) and two-sided p value. Given the difference
in risk profiles and frequencies of EGF A61G poly-
morphism between non-Asians in Los Angeles and
Chinese in Guangxi, we analyzed and presented the
results separately for the two populations. Subjects’ age,
sex, and race/ethnicity were included as covariates in all
logistic regression models. When examining the inde-
pendent effect of the EGF 61A > G polymorphism on
HCC risk, we included additional risk factors for HCC
in the logistic regression models: level of education,
smoking, alcohol consumption, and serology of HBV
and HCV infections.
Statistical analysis was conducted using the SAS soft-
ware Version 9.1 (SAS Institute, Cary, NC). All P values
quoted are two-sided. Two-sided P values that are 0.05
or less were considered statistically significant.
Results
The mean ages (±standard deviation) of HCC patients
and control subjects in Los Angeles, California, were
60.4 (±10.2) years and 59.3 (±10.7) years, respectively.
The corresponding figures in Guangxi, China were 49.3
(±9.6) and 49.5 (±10.3) years. In Los Angeles, there were
higher proportions of Hispanics and African-Americans
in cases than controls. HCC patients attained a lower
level of education than control subjects in the Los
Angeles study population, but there was no difference in
level of education between cases and control in the
Guangxi study population. The prevalence of cigarette
smoking, heavy use of alcohol, and positivity in hepatitis
B and/or C serology were significantly higher in HCC
patients than control subjects in both populations
(Table 1).
Table 2 shows the genotypic and allelic frequencies of
the EGF 61A > G polymorphism by race/ethnicity amongcontrols. There were no statistically significant differences
in genotypic or allelic frequencies between Han and
Zhuang/Yao Chinese in Guangxi, China whereas the
difference in genotypic and allelic frequencies between
non-Hispanic whites and Hispanics/blacks in Los Angeles,
California, was statistically significant (P = 0.0003). The G
allele frequencies of the EGF 61A >G polymorphism in
non-Asians and Chinese were 0.51 and 0.30, respectively
(2-sided P < 0.001). For both the Guangxi Chinese and the
Los Angeles non-Asians, their respective distribution of
the EGF 61A >G polymorphism was statistically compat-
ible with the Hardy-Weinberg equilibrium (Table 2).
Among non-Asians in Los Angeles, both the 61G/G
and the G/A genotypes of the EGF gene were associated
with an increased risk of HCC. There was no dose–re-
sponse relationship between the number of the 61*G
alleles and HCC risk. Compared with the A/A genotype,
individuals possessing the A/G or G/G genotypes had a
borderline statistically significant 78% increased risk of
developing HCC after adjustment for multiple risk
factors for HCC (Table 3). Among Chinese of Southern
Guangxi, no association between the EGF 61A > G poly-
morphism and HCC risk was noted (Table 3).
We also examined whether the EGF – HCC risk associ-
ation differed across different risk profiles as determined
by environmental exposures (use of tobacco or alcohol,
viral hepatitis serologic status) or the Th1/Th2 genotypes.
Among non-Asians in Los Angeles who consumed 3 or
more drinks of alcoholic beverages per day, the age-sex
-race-adjusted OR for HCC associated with the EGF A/G
or G/G genotype was 4.34 (95%CI = 1.37–13.74, P = 0.01)
compared with the A/A genotype (Table 3). Further ad-
justment for additional HCC risk factors slightly di-
minished the OR to 3.44 (95% CI = 0.93–12.76, P = 0.065).
Cigarette smoking or chronic infection with HBV and/or
HCV did not modify the association between EGF ge-
notype and HCC risk. All corresponding associations
between EGF genotype and HCC risk were null among
the Chinese in Guangxi (Table 3).
Table 4 shows the association between EGF genotype and
risk of HCC in low-risk non-Asians and high-risk Chinese,
respectively, stratified by Th1 and/or Th2 genotypes.
Among non-Asians with 2 or more low-activity Th1
genotypes, the EGF A/G or G/G genotypes was associated
with a borderline statistically significant increased risk
of HCC (OR = 2.77, 95% CI = 1.00–7.66, P = 0.049)
(Table 4). The corresponding OR among subjects with
1–2 low-activity Th2 genotypes was statistically significant
at 2.27 (95% CI = 1.01–5.11, P = 0.047). OR was further
increased to 3.34 (95% CI = 1.24–9.03, P = 0.017) for
individuals possessing the highest-risk Th1/Th2 combined
genotype profile. No such modifying effects of Th1 and/or
Th2 genotypes on HCC risk were noted among Chinese
in southern Guangxi, China.
Table 1 Distributions of demographic characteristics in hepatocellular carcinoma (HCC) patients and control subjects
by study location
Non-Asians in Los Angeles, California Chinese in southern Guangxi, China
Demographics HCC patients (n = 117) Control subjects (n = 225) HCC patients (n = 250) Control subjects (n = 245)
Age (years) 60.4 59.3 49.3 49.5
2-sided P 0.37 0.87
Sex (%)
Males 80 (68.4) 136 (60.4) 220 (88.0) 216 (88.2)
Females 37 (31.6) 89 (39.6) 30 (12.0) 29 (11.8)
2-sided P 0.15 0.96
Race/ethnicity (%)
Non-Hispanic white Americans 69 (59.0) 179 (79.6) . . . . . .
Hispanic Americans 39 (33.3) 34 (15.1) . . . . . .
African Americans 9 (7.7) 12 (5.3) . . . . . .
Chinese – Han ethnicity . . . . . . 198 (79.2) 196 (80.0)
Chinese – Zhuang/Yao ethnicity . . . . . . 52 (20.8) 49 (20.0)
2-sided P 0.0002 0.83
Level of education (%)
Below high school 22 (18.8) 17 (7.6) 115 (46.0) 102 (41.6)
High School graduates 32 (27.3) 51 (22.7) 79 (31.6) 87 (35.5)
Some college/occupational school 40 (34.2) 75 (33.3) 39 (15.6) 33 (13.5)
College graduates or above 23 (19.7) 82 (36.4) 17 (6.8) 23 (9.4)
2-sided P 0.001 0.47
Cigarette smoking
Non- or long ex-smokers 70 (59.8) 162 (72.0) 141 (56.4) 161 (65.7)
Current or recent ex-smokers 47 (40.2) 63 (28.0) 109 (43.6) 84 (34.3)
<20 cigarettes/day 14 (12.0) 26 (11.6) 33 (13.2) 28 (11.4)
≥20 cigarettes/day 33 (28.2) 37 (16.4) 76 (30.4) 56 (22.9)
2-sided 0.03 0.09
No. alcoholic drinks/day
Nondrinkers 35 (29.9) 74 (32.9) 158 (63.2) 205 (83.7)
<3 28 (23.9) 110 (48.9) 60 (24.0) 31 (12.7)
≥3 54 (46.2) 41 (18.2) 32 (12.8) 9 (3.7)
2-sided P <0.0001 <0.0001
Hepatitis B serology
Negative 84 (71.8) 198 (88.0) 45 (18.0) 212 (86.5)
Anti-HBc positive only 30 (25.6) 27 (12.0) . . . . . .
HBsAg positive 3 (2.6) 0 205 (82.0) 33 (13.5)
2-sided P 0.0002 <0.0001
Hepatitis C serology
Anti-HCV negative 59 (50.4) 224 (99.6) 241 (96.4) 242 (98.8)
Anti-HCV positive 58 (49.6) 1 (0.4) 9 (3.6) 3 (1.2)
2-sided P <0.0001 0.09
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Table 1 Distributions of demographic characteristics in hepatocellular carcinoma (HCC) patients and control subjects
by study location (Continued)
Hepatitis B/C serology
Both negative 54 (46.2) 198 (88.0) 45 (18.0) 210 (85.7)
Either positive† 63 (53.9) 27 (12.0) 205 (82.0) 35 (14.3)
2-sided P <0.0001 <0.0001
* Anti-HBC, antibodies to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; anti-HCV, antibodies to hepatitis C virus.
† Positive for hepatitis B surface antigen, antibodies to the hepatitis B surface antigen (for Los Angeles subjects only), or antibodies to hepatitis C virus.
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EGF induces hepatocyte proliferation in response to liver
injury, thereby facilitating liver regeneration [10]. Its role
in hepatocellular transformation has been studied both
in vitro and in vivo, showing that EGF enhanced hepato-
cyte transformation and that EGF over-expression in the
liver caused HCC [12,13]. A functional polymorphism at
position 61 has been described with G/G or A/G ge-
notypes associated with significantly higher EGF produc-
tion both in normal peripheral-blood mononuclear cell
cultures [14] and in serum and liver tissues of HCC
patients [15]. To our knowledge, population-based,
epidemiologic data examining the role of this poly-
morphism in HCC development were non-existent. The
present study shows a positive association between EGF
61A > G polymorphism and risk of HCC among low-risk
non-Asians in Los Angeles, California, especially among
those who were heavy users of alcohol or who possessed
a genetic Th1/Th2 profile linked to high HCC risk [22].
In contrast, no association between EGF genotype and
HCC risk was noted among the native population of
Southern Guangxi, China, who exhibit one of the highest
incidence of HCC in the world.
The difference in the EGF-HCC risk association be-
tween the Chinese in southern Guangxi and non-Asians
in Los Angeles could be due to the different allele fre-
quencies of EGF 61A > G polymorphism between the
two study populations. Compared with non-HispanicTable 2 The genotypic and allelic frequencies of the EGF poly
Genetic
polymorphism
Non-Asians in Los Angeles, California
Non-Hispanic whites (n = 179) Blacks/Hispanic
EGF 61A > G
A/A 0.21 0.50
A/G 0.48 0.33
G/G 0.31 0.17
A 0.45 0.66
G 0.55 0.34
2-sided P for HW† 0.81 0.07
2-sided P‡ 0.0003
* Test for differences in genotypic frequencies between the four racial/ethnic group
† Test for the Hardy-Weinberg linkage equilibrium within each racial/ethnic group.
‡ Test for differences in genotypic frequencies between the two racial/ethnic groupwhites in Los Angeles, Chinese in Guangxi had a signifi-
cantly lower frequency of the 61*G allele of the EGF
gene (55% versus 30%).
We also conjecture that the huge difference in risk of
HCC between the Chinese in Southern Guangxi (120/
100,000 person-years in men) and the non-Asians of Los
Angeles (4/100,000 person-years in men) may be one
explanation for the seemingly disparate findings in the
EGF-HCC association between the two populations. If
the EGF genotype effect on HCC occurrence is inde-
pendent of the combined effect from other risk factors,
then the statistical power to detect a given EGF-HCC
association should not be influenced by the population’s
background level of HCC risk. In other words, a multi-
plicative model of interaction between EGF genotype
and background risk factors means one would observe
the same magnitude of EGF-HCC association between
low-risk non-Asians and high-risk native Chinese whose
background level of risk vary by a factor of 30 (120/
100,000 versus 4/100,000). But suppose the interaction
model is additive rather than multiplicative, then a two-
fold risk between low- versus high-risk EGF profile in
non-Asians (the result reported here) would translate to
a relative risk of 1.07 (32/30) in Chinese of Southern
Guangxi. In other words, an additive model of inter-
action between EGF genotype and background risk
factors would predict a null finding among the high-risk
Chinese.morphism among control subjects by race/ethnicity
Chinese in southern Guangxi, China
s (n = 46) Han Chinese (n = 196) Zhuang/Yao Chinese (n = 49)
0.48 0.49
0.43 0.45
0.09 0.06
0.70 0.71
0.30 0.29
0.72 0.48
0.84
s.
s within a given study location.
Table 3 Comparison of EGF genotype frequencies in HCC patients with control subjects among non-Asians in Los
Angeles, California, and Chinese in southern Guangxi, China
Subgroup EGF 61A > G Non-Asians in Los Angeles Chinese in southern Guangxi
Ca/Co* OR (95% CI)† OR (95% CI)‡ Ca/Co* OR (95% CI)† OR (95% CI)‡
All subjects A/A 28/60 1.00 1.00 126/118 1.00 1.00
A/G 61/102 1.61 (0.89–2.90) 2.04 (1.03–4.07) 99/107 0.87 (0.60–1.26) 0.69 (0.41–1.18)
G/G 28/63 1.34 (0.68–2.64) 1.39 (0.64–3.01) 25/20 1.17 (0.62–2.22) 0.97 (0.38–2.46)
A/G + G/G 89/165 1.52 (0.87–2.65) 1.78 (0.93–3.38) 124/127 0.91 (0.64–1.30) 0.73 (0.44–1.21)
Seronegative for all viral
hepatitis markers
A/A 12/52 1.00 1.00 26/101 1.00 1.00
A/G + G/G 42/146 1.65 (0.76–3.55) 1.95 (0.86–4.41) 19/109 0.65 (0.33–1.27) 0.61 (0.30–1.23)
Seropositive for any viral
hepatitis markers§
A/A 16/8 1.00 1.00 100/17 1.00 1.00
A/G + G/G 47/19 1.43 (0.50–4.07) 1.62 (0.50–5.27) 105/18 0.91 (0.44–1.88) 0.88 (0.41–1.87)
Non-drinkers or <3 drinks of
alcoholic beverages per day
A/A 16/45 1.00 1.00 114/115 1.00 1.00
A/G + G/G 47/139 1.12 (0.56–2.23) 1.60 (0.72–3.52) 104/121 0.86 (0.60–1.25) 0.75 (0.45–1.26)
3+ drinks of alcoholic
beverages per day
A/A 12/15 1.00 1.00 12/3 1.00 1.00
A/G + G/G 42/26 4.34 (1.37–13.74) 3.44 (0.93–12.76) 20/6 0.74 (0.12–4.70) 0.32 (0.02–4.83)
Non-smokers or long-term
ex-smokers¶
A/A 17/40 1.00 1.00 71/78 1.00 1.00
A/G + G/G 53/122 1.55 (0.75–3.21) 1.86 (0.83–4.18) 70/83 0.92 (0.58–1.45) 0.83 (0.44–1.57)
Current smokers or recent
ex-smokers¶
A/A 11/20 1.00 1.00 55/40 1.00 1.00
A/G + G/G 36/43 1.59 (0.63–3.99) 1.52 (0.50–4.63) 54/44 0.87 (0.49–1.54) 0.51 (0.21–1.23)
* Number of cases/number of controls.
† Adjusted for age, sex, and race; OR, odds ratio; CI, confidence interval.
‡ Further adjusted for level of education, smoking (non-smokers or long-term ex-smokers, current smokers or recent ex-smokers with <20 cigarettes/day, current
smokers or recent ex-smokers with 20+ cigarettes/day), alcohol consumption (non-drinkers, <7, 7–14, 14–21, and 21+ drinks/day), and serology of hepatitis B and
C virus. In subgroup analyses, the stratifying variable was not input as a covariate.
§ Positive for hepatitis B surface antigen, antibodies to hepatitis B core antigen, or antibodies to hepatitis C virus.
¶ Subjects who quit smoking 10 or more years ago were long-term ex-smokers whereas those who quit smoking less than 10 years ago were recent ex-smokers.
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on the association between EGF and HCC is not surpris-
ing, given the well-established interplay of NF-κB and
JAK-STAT pathways and cytokine/growth factor signal-
ing in liver regeneration. It’s been proposed that
cytokines (predominantly TNFα)-mediated NF-κB acti-
vation causes “priming” of hepatocytes to enhance their
sensitivity to direct mitogens (such as EGF) in the
process of liver regeneration [25]. In addition, growth
factors (including EGF) can act as alternative “rescue”
activators of NF-κB in the absence of main cytokine
signaling [26]. Similarly, STAT3, an important member
of the JAK-STAT pathway, is activated by both EGF and
cytokines (IL-10, IL-6), and has been proposed to play a
central role in viral-induced HCC [27], where IL-6 and
EGF were shown to act in concert to promote expression
of HBV viral genes [28]. Thus, utilization of common
signaling pathways (NF-κB, STAT3) by inflammatory and
growth factors provides a framework for their collabor-
ation in liver carcinogenesis [27].
The present study also suggests a role of the EGF 61A
> G polymorphism in the development of HCC among
low-risk non-Asians of Los Angeles who were heavy users
of alcohol. EGF can modulate the effect of ethanol on cell
proliferation and DNA synthesis [27,29]. A recent studydemonstrated that EGF-like growth factors can reduce
apoptosis and enhance cell proliferation caused by expos-
ure to alcohol [30]. Given that reduced apoptosis and
enhanced cell proliferation are hallmarks of carcino-
genesis, these experimental results suggest a plausible
biological mechanism for the modifying effect of the EGF
genetic polymorphism on HCC development among
heavy drinkers.
Heavy alcohol consumption is an important risk factor
for HCC in non-Asians in Los Angeles. Forty-six percent
(n = 54) of HCC patients and 18% of control subjects
consumed 3 or more drinks per day among non-Asians
in Los Angeles. Of the 54 HCC patients consuming 3 or
more alcoholic beverages per day, 22 (41%) were free of
HBV or HCV serological markers, two primary risk
factors for HCC, indicating that heavy alcohol consump-
tion plays an important role in the HCC development in
low-risk non-Asians in Los Angeles, California. In con-
trast, only 13% (n = 32) Chinese HCC patients and 4%
Chinese controls in Guangxi consumed 3 or more drinks
of alcoholic beverages per day. Among the 32 HCC
patients who consumed 3 or more alcohol drinks per
day, 26 (81%) also tested positive for HBsAg and/or anti-
HCV. In addition, dietary exposure to aflatoxin has been
identified as another major risk factor for HCC in this
Table 4 Comparison of EGF genotype frequencies in HCC patients with control subjects among non-Asians in Los
Angeles, California, and Chinese in southern Guangxi, China, stratified by cytokine genotypes
Th1 and Th2
genotypes*
EGF 61A > G Non-Asians in Los Angeles Chinese in southern Guangxi
Ca/Co* OR (95% CI)† OR (95% CI)‡ Ca/Co* OR (95% CI)† OR (95% CI)‡
No. of low-activity Th1 genotypes
0–1 A/A 13/27 1.00 (ref) 1.00 (ref) 70/76 1.00 (ref) 1.00 (ref)
A/G + G/G 38/86 1.14 (0.50–2.63) 1.24 (0.46–3.34) 61/77 0.87 (0.54–1.39) 0.63 (0.32–1.23)
2–3 A/A 11/25 1.00 (ref) 1.00 (ref) 55/42 1.00 (ref) 1.00 (ref)
A/G + G/G 50/60 2.17 (0.91–5.18) 2.77 (1.00–7.66) 63/50 0.95 (0.55–1.65) 0.89 (0.40v1.97)
No. of low-activity Th2 genotypes
0 A/A 7/13 1.00 (ref) 1.00 (ref) 72/61 1.00 (ref) 1.00 (ref)
A/G + G/G 18/28 1.85 (0.48–7.15) 1.36 (0.23–8.27) 55/48 0.97 (0.58–1.63) 0.78 (0.36–1.69)
1–2 A/A 17/39 1.00 (ref) 1.00 (ref) 53/57 1.00 (ref) 1.00 (ref)
A/G + G/G 70/118 1.63 (0.83–3.20) 2.27 (1.01–5.11) 69/79 0.95 (0.58–1.56) 0.84 (0.42–1.71)
No. of low-activity Th1 and Th2 genotypes
Th1 = 0–1 and Th2 = 1–2 A/A 13/19 1.00 (ref) 1.00 (ref) 35/31 1.00 (ref) 1.00 (ref)
A/G + G/G 33/70 0.86 (0.36–2.04) 0.95 (0.33–2.70) 36/48 0.69 (0.36–1.33) 0.57 (0.21–1.54)
Th1 = 2–3 or Th2 = 0 A/A 11/33 1.00 (ref) 1.00 (ref) 90/87 1.00 (ref) 1.00 (ref)
A/G + G/G 55/76 2.75 (1.18–6.38) 3.34 (1.24–9.03) 88/79 1.07 (0.70–1.63) 0.85 (0.47–1.56)
* Number of cases/number of controls; subjects with unknown Th1 and/or Th2 genotypes were excluded from this analysis.
† Adjusted for age, sex, and race; OR, odds ratio; CI, confidence interval.
‡ Further adjusted for level of education, smoking (non-smokers or long-term ex-smokers, current smokers or recent ex-smokers with <20 cigarettes/day, current
smokers or recent ex-smokers with 20+ cigarettes/day), alcohol consumption (non-drinkers, <7, 7–14, 14–21, and 21+ drinks/day), and serology of hepatitis B and
C virus, if applicable.
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take per se plays a relatively minor role in contributing
to the burden of HCC in this Chinese population.
The association between EGF 61A > G and the risk of
developing HCC was initially reported in two independ-
ent cohorts of cirrhotic patients; cirrhotic patients po-
ssessing the EGF 61 G/G genotype had 2- to 4-fold
increased risk of HCC compared with cirrhotic patients
with the EGF 61A/A genotype [15]. These initial findings
were replicated in the Hepatitis C Antiviral Long-term
Treatment against Cirrhosis (HALT-C) trial cohort;
hepatitis C patients with an Ishak fibrosis stage of 3 or
higher and possessing the EGF 61 G/G genotype
experienced a doubling HCC risk relative to their coun-
terparts with the EGF 61A/A genotype [31]. Although
these studies provided a strong support for a role of
EGF genetic polymorphism in the progression of liver
disease from fibrosis/cirrhosis to malignant stage, these
data provide no information on the relationship between
EGF genetic polymorphism and risk of HCC in a general
population as discussed by Galmozzi and Colombo [32].
It should be noted that the average EGF G allele
frequency among the HCC patients of the two studies
described above was 58% [15,31], which was virtually
identical to the percentage noted in white HCC patients
in the present study (57%).
There were two recent reports of meta-analysis on the as-
sociation between the EGF 61A >G genetic polymorphismsand risk of HCC in Caucasians, Chinese or mixed races
[33,34]. The latter meta-analysis [34] was based on data
from 8 case–control studies totaling 1304 HCC cases
and 2613 controls, which included all six case–control
studies examined in the first meta-analysis report [33].
This latter meta-analysis yielded a summary OR of 1.79
(95% CI = 1.39–2.29) for the EGF 61 G/G versus the A/
A genotype [34]. Significantly, this positive association
between EGF 61A > G polymorphism and HCC was
seen only hospital-based studies utilizing hospital
controls. No association was observed among studies
utilizing population-based controls. In other words, the
overall null association noted in the present study is
consistent with published literature.
There are inherent limitations in the present study
that have been previously described [22,23]. Briefly, both
studies were of relatively small sample size. Thus, we
were unable to conduct separate analyses for non-
Hispanic white Americans and Hispanics/blacks, in spite
of their differences in allele frequencies of EGF 61A > G
polymorphism. Although race was one of the matching
factors for the original study design, the imbalance in
the race/ethnic distribution between HCC patients and
controls of the Los Angeles study was the results of a
greater proportion of black and Hispanic controls who
refused to donate blood samples [6]. In addition, the
majority of eligible patients died before we were able to
approach them for study participation due to the rapidly
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Nonetheless, demographic features of eligible patients
who were excluded from the study were similar to those
who participated in our study. For the study in Guangxi,
China, we were unable to review medical charts or obtain
liver tissue slides to confirm the diagnosis of HCC and to
estimate the prevalence of cirrhosis among HCC patients.
If cirrhosis might modulate the influence of EGF poly-
morphism on HCC risk, the difference in the underlying
etiologies for HCC between Chinese population in China
(e.g., hepatitis B and dietary aflatoxin exposure) and non-
Asians in Los Angeles (e.g., hepatitis C and alcohol abuse)
could explain partially the observed differences in the
EGF-HCC risk association between the two study
populations since some of HCC patients with hepatitis B
as the underlying cause did not show cirrhosis in the liver.
Conclusions
The polymorphism in EGF gene associated with its in-
creased expression was linked to HCC development in a
low-risk non-Asian population, while no such associ-
ation was observed in a high-risk Chinese population.
Among the low-risk non-Asians, the EGF gene-HCC risk
associations were confined to heavy alcohol drinkers and
subjects possessing the high-risk Th1/Th2 genotypic
profiles.
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